Open AccessProadrenomedullin Predicts Severe Disease in Children With Suspected Community-acquired Pneumonia
Author(s) -
Todd A. Florin,
Lilliam Ambroggio,
Cole Brokamp,
Yin Zhang,
Eric Nylen,
Mantosh S. Rattan,
Eric J. Crotty,
Michael A. Belsky,
Sara Krueger,
Thomas N. Epperson,
Andrea Kachelmeyer,
Richard M. Ruddy,
Samir S. Shah
Publication year - 2020
Publication title -
clinical infectious diseases/clinical infectious diseases (online. university of chicago. press)
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.44
H-Index - 336
eISSN - 1537-6591
pISSN - 1058-4838
DOI - 10.1093/cid/ciaa1138
Subject(s) - medicine , pneumonia , community acquired pneumonia , intensive care medicine , disease , pediatrics
Proadrenomedullin (proADM), a vasodilatory peptide with antimicrobial and anti-inflammatory properties, predicts severe outcomes in adults with community-acquired pneumonia (CAP) to a greater degree than C-reactive protein and procalcitonin. We evaluated the ability of proADM to predict disease severity across a range of clinical outcomes in children with suspected CAP.